Analysis

ConjuChem's modified GHRH analogue with a Drug Affinity Complex (DAC) tail extending the half-life from minutes to roughly 8 days. Teichman 2006 (J Clin Endocrinol Metab) is the foundational human pharmacokinetic study. Subsequent development was limited; CJC-1295 did not advance beyond Phase 1/2.

CJC-1295 is a synthetic GHRH analogue based on the GRF(1-29) sequence, modified with a Drug Affinity Complex (DAC) tail that binds reversibly to circulating albumin and extends the half-life from approximately 7 minutes (native GHRH) to roughly 8 days. Teichman 2006 (JCEM) is the foundational human PK study and the basis for the once-weekly dosing rationale that subsequent research-peptide protocols inherited. The mechanism case is strong: pulsatile GH release stimulation at the pituitary, with downstream IGF-1 elevation. The development pathway never advanced beyond Phase 1/2, ConjuChem's clinical program shifted away from CJC-1295 in the late 2000s, and the molecule has not been picked up by another sponsor for regulated development since. Methodology v1.2 scores CJC-1295 5.2, mechanism clean, human dossier sparse beyond the foundational PK paper. The peptide remains heavily marketed in the research channel, often paired with ipamorelin in dual-protocol marketing, that combination has no published Phase 2 efficacy data and the protocol marketing pattern is one of the more visible examples of mechanism-storytelling outpacing trial evidence. WADA prohibits CJC-1295 under Class S2; athletic populations should not use the molecule.